580,594 Shares in Allergan PLC (AGN) Acquired by Johnston Asset Management LLC
Johnston Asset Management LLC bought a new position in Allergan PLC (NYSE:AGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 580,594 shares of the company’s stock, valued at approximately $134,170,000. Allergan PLC comprises 6.8% of Johnston Asset Management LLC’s investment portfolio, making the stock its 3rd largest position. Johnston Asset Management LLC owned 0.15% of Allergan PLC as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in AGN. Barnett & Company Inc. acquired a new stake in Allergan PLC during the first quarter worth about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new stake in Allergan PLC during the second quarter worth about $125,000. Trust Co. of Vermont raised its stake in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the period. Ropes Wealth Advisors LLC raised its stake in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares during the period. Finally, Integrated Investment Consultants LLC raised its stake in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares during the period. Institutional investors own 85.19% of the company’s stock.
Shares of Allergan PLC (NYSE:AGN) traded up 1.06% during mid-day trading on Monday, hitting $232.75. 3,154,753 shares of the company traded hands. The firm has a market cap of $92.16 billion, a price-to-earnings ratio of 22.16 and a beta of 0.81. Allergan PLC has a 52-week low of $195.50 and a 52-week high of $322.68. The firm has a 50-day moving average price of $242.33 and a 200 day moving average price of $240.70.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.34 by $0.01. The business earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The business’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.41 earnings per share. Equities research analysts anticipate that Allergan PLC will post $14.00 EPS for the current fiscal year.
A number of equities research analysts have issued reports on AGN shares. Zacks Investment Research upgraded shares of Allergan PLC from a “hold” rating to a “buy” rating and set a $274.00 target price on the stock in a report on Friday, July 15th. Vetr lowered shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $272.10 target price on the stock. in a report on Thursday, July 14th. Bank of America Corp. reiterated a “buy” rating and set a $294.00 target price (up from $287.00) on shares of Allergan PLC in a report on Wednesday, June 29th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Allergan PLC in a report on Wednesday, July 6th. Finally, Leerink Swann reissued a “buy” rating on shares of Allergan PLC in a research report on Thursday, June 30th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $300.64.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.